Today we publish our interim report focusing closely on the performance of the company the first six months of 2023. Watch this video with CEO of Gubra Henrik Blou where he covers most of it in 3 minutes. Contacts at…
Gubra and Bayer started the collaboration in 2021 Gubra will actively (alone or with a new partner) continue further development of the cardio-renal metabolic peptide programme Gubra sees great potential for this drug programme within the area of healthy weight…
Today, Gubra announces the signing of an agreement with Hemab concerning a peptide collaboration. Under the terms of this pre-collaboration agreement, Gubra will start working on identifying peptide modulators suitable as a treatment for certain bleeding disorders. Gubra will utilize…
Today, Gubra announces preliminary Q2 and H1 2023 revenue figures for the CRO business and revises its revenue outlook for 2023 upwards, driven by strong performance in Q2 2023 as well as current trading and solid orderbook. The 2023 outlook…
On 30 June, 2023, Gubra A/S (“Gubra” or the “Company”) announced that a share buy-back programme of approximately DKK 2.5 million and up to a maximum of 27,231 shares has been initiated with the purpose of meeting the Company's obligations…
Gubra A/S (“Gubra” or the “Company”) today announces the initiation of a share buy-back programme, pursuant to which the Company intends to buy back up to 27,231 of its own shares. The purpose of the share buy-back programme is to…
Today, Gubra announces the acquisition of the Danish minipig service provider MiniGut ApS. MiniGut ApS is a fully equipped minipig contract research organisation (CRO) located at DTU Science Park in Hørsholm, Denmark, next to the headquarters of Gubra. The acquisition…
Gubra today announces updates to its R&D pipeline of internal and partnered projects. Most notably is the addition of a new CNS (orexin) peptide drug discovery project, now ready for partnering. The aim of the project is to develop an…
Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in…
Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company”) hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in…